HYPR Hyperfine, Inc.
$0.79▲ +0.47%
Healthcare
Other
After hours
$0.83▲ +4.99%
Sep 11, 7:59 PM ET
Volume 189.0K
Avg Volume (10D) 408.6K
Key Metrics & Fundamentals
Market Cap
$83.79M
P/E Ratio
–
Div Yield
–%
52W Range
0.78 - 2.22
% vs 50 MA
-16.31%
% vs 200 MA
-32.40%
RSI-14
31.2
MACD Histogram
+0.0000
Beta (1Y vs SPY)
2.40
Free Cash Flow
-$7.30M
Gross Rev
$3.90M
Gross Profit
$1.98M
EBITDA
-$7.93M
COGS
$1.92M
Operating Exp
$10.45M
Operating Income
-$8.47M
EBIT
-$8.47M
Pretax Income
-$9.30M
Net Income
-$9.30M
EPS (Diluted)
-0.09
Price & Volume History
Loading chart…
Recent News
Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference
Business Wire · Aug 31, 2026 12:15 PM
Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans
Business Wire · Aug 26, 2026 12:15 PM
Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings
Business Wire · Aug 20, 2026 12:15 PM
Hyperfine (HYPR) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 14, 2026 12:16 AM
Hyperfine, Inc. Q2 2026 Earnings Call Summary
Moby · Aug 7, 2026 12:30 PM
Hyperfine Inc (HYPR) (Q2 2026) Earnings Call Highlights: Revenue Surges 45% on Strong System ...
GuruFocus.com · Aug 7, 2026 5:06 AM
Hyperfine Q2 Earnings Call Highlights
MarketBeat · Aug 7, 2026 3:03 AM
Hyperfine, Inc. (HYPR) Reports Q2 Loss, Lags Revenue Estimates
Zacks · Aug 6, 2026 11:10 PM
Hyperfine, Inc. Reports Second Quarter 2026 Financial Results
Business Wire · Aug 6, 2026 8:05 PM
RxSight, Inc. (RXST) Reports Q2 Loss, Beats Revenue Estimates
Zacks · Aug 5, 2026 10:10 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See HYPR's money flow as a full page
Social Sentiment
No Reddit posts found for HYPR.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.